Acquiring Company
Barinthus Biotherapeutics plc
Acquired Company
Clywedog Therapeutics
OxfordTraffordBiotechnologyTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Barinthus Biotherapeutics is set to complete its merger with Clywedog Therapeutics in an all-stock transaction, effective September 3, 2026. As a result, Barinthus will cease trading on Nasdaq, while the merged entity will commence under the ticker symbol 'CLYD.' The Scheme Exchange Ratio has been set at 0.111, ensuring compliance with Nasdaq listing requirements.
Don't miss Barinthus Biotherapeutics plc's next move
Get an email the moment Barinthus Biotherapeutics plc makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Clywedog Therapeutics?
Clywedog Therapeutics was acquired by Barinthus Biotherapeutics plc, based in Oxford. The deal was reported on August 24, 2026. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Barinthus Biotherapeutics plc is publicly traded (BRNS) and operates in Biotechnology.
When did Barinthus Biotherapeutics plc acquire Clywedog Therapeutics?
Barinthus Biotherapeutics plc's acquisition of Clywedog Therapeutics was reported on August 24, 2026. Barinthus Biotherapeutics is set to complete its merger with Clywedog Therapeutics in an all-stock transaction, effective September 3, 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Clywedog Therapeutics do?
Clywedog Therapeutics, Inc. is a private company dedicated to advancing novel breakthrough medicines in diabetes and autoimmune diseases. The company focuses on developing clinical-stage candidates for metabolic disorders. It is privately held, operating in Biotechnology, and is based in Trafford.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.